Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) AI Stock Analysis

• Market Cap: HK$30.34B
• Dividend Yield: N/A
• Average Volume (3M): 5.91M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.20
• Revenue Growth: 112.97%
• EPS Growth: 37.70%
• Country: HK
• Employees: 450
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.12
• Shares Outstanding: 1,024,730,800
• 10 Day Avg. Volume: 5,228,361
• 30 Day Avg. Volume: 5,906,894
• PEG Ratio: 0.36
• Price to Book (P/B): 31.04
• Price to Sales (P/S): 33.57
• P/FCF Ratio: -25.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: HK$30.00 ▲(22.75% Upside)

The score is held down primarily by weak financial performance, especially persistent losses and negative operating/free cash flow, alongside leverage risk. Technicals are a positive offset with strong trend and momentum, while valuation support is limited due to negative earnings and no dividend data.

Positive Factors

Rapid revenue growth

Sustained triple-digit revenue expansion signals strong adoption of MedBot's robotic systems and instruments, providing a larger recurring revenue base. Over the medium term this top-line momentum can fund scale efficiencies, R&D and commercialization if margins improve.

Recurring and diversified revenue streams

A business model combining upfront capital sales with consumables, service contracts and training partnerships creates predictable lifecycle revenue and customer lock-in. This mix supports margin sustainability and long‑term cash conversion as installed base grows.

Strategic position in surgical robotics amid secular demand

Operating in a growing, structural market for minimally invasive and robotic surgery gives durable addressable-market expansion. As a focused robotics player, MedBot benefits from secular adoption, clinical partnerships and potential network effects from training and installations.

Negative Factors

Negative operating and free cash flow

Persistent negative operating and free cash flow constrains internal funding for production scale, service rollout and R&D. Over months this forces reliance on external financing, increasing dilution or interest burden and limiting the firm’s financial flexibility to execute growth plans.

Ongoing net losses and weak margins

Continued net losses and negative operating margins indicate structural cost or pricing gaps. Without sustained margin improvement, the company may struggle to convert revenue growth into sustainable profits, limiting reinvestment capacity and shareholder returns over the medium term.

Moderately high leverage and declining equity ratio

Elevated leverage and a falling equity ratio reduce balance-sheet resilience, increasing vulnerability to revenue shocks. With negative ROE, debt amplifies financial risk and could restrict access to affordable capital, pressuring liquidity and strategic initiatives over the coming months.

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.

How the Company Makes Money

The company generates revenue primarily through the sale of its robotic surgical systems and associated instruments, which are sold to hospitals and surgical centers. Key revenue streams include upfront sales of robotic systems, recurring revenue from the sale of consumable instruments, and maintenance contracts for ongoing support and upgrades. Additionally, MicroPort MedBot engages in partnerships with healthcare institutions for clinical studies and training programs, which further contribute to its revenue. The increasing demand for minimally invasive surgical procedures and the expansion of its product portfolio are significant factors driving its earnings.

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Financial Statement Overview

Summary

Despite strong revenue growth, profitability remains weak with continued net losses and negative EBIT/EBITDA margins. Balance sheet leverage is moderately high and ROE is negative, while cash flow is a key risk with negative operating cash flow and free cash flow.

Income Statement

The company has shown significant revenue growth over the past few years, with Total Revenue increasing from 2.15 million in 2021 to 257.25 million in 2024. However, profitability remains a concern with negative Net Income and high negative EBIT and EBITDA margins, indicating operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company's Debt-to-Equity ratio is moderately high, reflecting a high level of leverage which could be risky if not managed properly. The Equity Ratio has been decreasing, indicating a declining proportion of equity financing. Return on Equity is negative due to net losses, suggesting challenges in generating returns for shareholders.

Cash Flow

The company struggles with negative Free Cash Flow and Operating Cash Flow, which raises concerns about its ability to generate cash internally. The lack of positive cash flow from operations could limit growth and investment opportunities unless addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	333.70M	257.25M	104.59M	21.60M	2.15M	0.00
Gross Profit	110.71M	86.22M	14.69M	6.56M	919.00K	0.00
EBITDA	-275.57M	-413.34M	-893.36M	-1.05B	-543.84M	-160.93M
Net Income	-478.60M	-642.41M	-1.01B	-1.14B	-582.92M	-208.87M
Balance Sheet
Total Assets	1.50B	1.28B	1.43B	1.93B	2.79B	1.70B
Cash, Cash Equivalents and Short-Term Investments	815.79M	612.23M	507.71M	747.96M	1.94B	1.50B
Total Debt	668.22M	691.33M	560.42M	219.95M	204.68M	19.24M
Total Liabilities	985.94M	1.02B	926.15M	522.25M	401.73M	262.90M
Stockholders Equity	535.11M	278.20M	519.48M	1.42B	2.39B	1.44B
Cash Flow
Free Cash Flow	-233.38M	-340.21M	-634.30M	-1.09B	-674.47M	-118.05M
Operating Cash Flow	-205.18M	-298.12M	-567.84M	-898.48M	-540.49M	-103.04M
Investing Cash Flow	-32.22M	-47.60M	-58.38M	-267.82M	-396.57M	-15.01M
Financing Cash Flow	833.81M	449.96M	385.68M	-27.95M	1.39B	1.56B

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.44
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2252, the sentiment is Positive. The current price of 24.44 is below the 20-day moving average (MA) of 27.50, above the 50-day MA of 24.27, and above the 200-day MA of 22.08, indicating a bullish trend. The MACD of 1.52 indicates Negative momentum. The RSI at 56.85 is Neutral, neither overbought nor oversold. The STOCH value of 48.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2252.

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	69 Neutral	HK$6.46B	20.18	11.24%	1.26%	25.18%	55.79%
2172	69 Neutral	HK$7.08B	32.02	11.79%	1.50%	-5.18%	-9.69%
1302	57 Neutral	HK$7.43B	104.49	1.98%	―	3.42%	-70.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2252	46 Neutral	HK$30.34B	-54.19	-117.51%	―	112.97%	37.70%
0853	46 Neutral	HK$23.24B	-17.37	-24.77%	―	-1.04%	60.66%
2160	43 Neutral	HK$5.54B	386.36	0.22%	―	-4.38%	―

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Corporate Events

MicroPort MedBot Forecasts Revenue Surge and Sharply Narrowed Loss on Toumai Robot Boom

Shanghai MicroPort MedBot expects its 2025 revenue to grow by about 110% to 120% year on year, driven primarily by breakthrough commercialization of its flagship Toumai laparoscopic surgical robot. Toumai has gained strong traction overseas, securing more than 100 new overseas orders in 2025 and boosting international sales revenue to over five times the previous year, bringing total global commercial orders above 180 and installed units beyond 120. The group also anticipates a substantial narrowing of its adjusted net loss to no more than RMB240 million, more than halving from 2024, helped by rapid revenue growth and cost-cutting and efficiency measures, while net free cash outflow is projected to shrink by over 80% to no more than RMB70 million, indicating improving operational efficiency and a strengthening financial profile for investors to watch as the business scales.

The most recent analyst rating on (HK:2252) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

MicroPort MedBot Wins NMPA Approval for UniPath Bronchoscopic Surgical Robot

Shanghai MicroPort MedBot (Group) Co., Ltd. has obtained approval from China’s National Medical Products Administration for its self-developed UniPath Electronic Bronchoscopic Surgical Robotic System, a non-invasive natural orifice platform designed for early diagnosis and treatment of deep and peripheral pulmonary lesions such as micronodules. The approval lifts the company’s portfolio of approved surgical robot products to seven and makes it, according to the announcement, the first enterprise globally to commercialise a full spectrum of robotic systems across five major and fast-growing surgical specialties, reinforcing its technological depth and signaling a transition toward large-scale development of its domestic surgical robot ecosystem.

The most recent analyst rating on (HK:2252) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

MicroPort MedBot’s Toumai Surgical Robot Surpasses 100 Global Commercial Installations

Shanghai MicroPort MedBot announced that cumulative orders for its core robotic surgery products have surpassed 230 units, with its flagship Toumai laparoscopic surgical robot accounting for more than 160 commercial orders globally and ranking among the top two worldwide by 2025 order volume. The company has now completed over 150 commercial installations across its product range, including more than 100 Toumai units that meet revenue recognition criteria under HKFRS, making Toumai the first domestic laparoscopic surgical robot to reach the 100-unit commercial installation milestone. Management highlighted that this scale demonstrates system reliability, clinical stability and strengthened capabilities in quality, production and delivery, while domestically Toumai has gained strong traction in leading hospitals, with over 90% of installations in Grade‑IIIA facilities and 23% in China’s top 100 hospitals, helping diffuse advanced robotic surgery from top-tier centers to regional and primary hospitals. Internationally, Toumai’s footprint now spans over 40 countries and regions, achieving multi-unit sales and multi-hospital deployments in 15 markets and underpinning a growing global robotic surgery ecosystem that integrates top experts, regional medical centers and primary hospitals, reinforcing the company’s competitive positioning in the rapidly expanding medical robotics industry.

The most recent analyst rating on (HK:2252) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

Shanghai MicroPort MedBot Strengthens Audit Committee Governance

Shanghai MicroPort MedBot (Group) Co., Ltd. has established terms of reference for its Audit Committee to enhance decision-making and oversight processes. The Audit Committee is tasked with supervising internal and external audits, ensuring effective internal controls, and providing accurate financial reporting, thereby strengthening the company’s governance and operational transparency.

The most recent analyst rating on (HK:2252) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

Shanghai MicroPort MedBot Enhances Governance with New Nomination Committee

Shanghai MicroPort MedBot (Group) Co., Ltd. has established a Nomination Committee under its board of directors to enhance corporate governance and streamline the appointment process for directors and senior management. This move aims to optimize board composition and succession planning, ensuring that the company is well-positioned to address future challenges and opportunities.

The most recent analyst rating on (HK:2252) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

Shanghai MicroPort MedBot Enhances Corporate Governance with New Committee

Shanghai MicroPort MedBot (Group) Co., Ltd. has established a Remuneration and Appraisal Committee under its board of directors to enhance corporate governance. This committee is responsible for formulating appraisal standards and reviewing remuneration policies for directors, supervisors, and senior management, which is expected to optimize the company’s management system and accountability.

The most recent analyst rating on (HK:2252) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

Shanghai MicroPort MedBot Establishes Strategy and Development Committee

Shanghai MicroPort MedBot (Group) Co., Ltd. announced the establishment of a Strategy and Development Committee under its board of directors. This committee is tasked with researching and proposing long-term development strategies and major decisions to strengthen the company’s strategic development, optimize investment decision procedures, and improve decision-making effectiveness. The committee will also review and evaluate the company’s financial, marketing, operational, and business performance, as well as study market trends and their potential effects on the company’s growth.

The most recent analyst rating on (HK:2252) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

Shanghai MicroPort MedBot Announces Key Appointments and Governance Changes at 2025 EGM

Shanghai MicroPort MedBot (Group) Co., Ltd. held its 2025 Extraordinary General Meeting (EGM) on November 25, 2025, where several key resolutions were passed. These included the appointment of new directors and amendments to the Articles of Association and Rules of Procedure, reflecting the company’s strategic direction and governance enhancements. The successful passing of these resolutions indicates a strong shareholder support and positions the company for future growth and operational efficiency.

The most recent analyst rating on (HK:2252) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

Shanghai MicroPort MedBot Announces EGM for Board Appointments and Governance Amendments

Shanghai MicroPort MedBot (Group) Co., Ltd. has announced an extraordinary general meeting scheduled for November 25, 2025, to discuss several key appointments to its board of directors, including both non-executive and independent non-executive roles. Additionally, the meeting will address proposed amendments to the company’s Articles of Association and the Rules of Procedure for the General Meeting of Shareholders, which could impact the company’s governance and operational procedures.

The most recent analyst rating on (HK:2252) stock is a Buy with a HK$42.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

Shanghai MicroPort MedBot Announces Board Reshuffle

Shanghai MicroPort MedBot (Group) Co., Ltd. announced significant changes in its board of directors, with the resignation of Mr. Sun Hongbin, Ms. Fang Cong, and Dr. Li Minghua, who are stepping down to focus on other business commitments. The company has proposed the appointment of Dr. Chang Zhaohua, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, and Ms. Liang Min as new non-executive directors, pending shareholder approval. These changes are expected to bring new perspectives and expertise to the board, potentially impacting the company’s strategic direction and strengthening its position in the medical device industry.

The most recent analyst rating on (HK:2252) stock is a Buy with a HK$42.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.